253 related articles for article (PubMed ID: 9559795)
1. Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults.
Tod M; Lortholary O; Seytre D; Semaoun R; Uzzan B; Guillevin L; Casassus P; Petitjean O
Antimicrob Agents Chemother; 1998 Apr; 42(4):849-56. PubMed ID: 9559795
[TBL] [Abstract][Full Text] [Related]
2. [Assessment of pharmacokinetic parameters of amikacin in a group of neutropenic patients in onco-hematology].
Pivot-Dumarest C; Deweerdt C; Troncy J; Sorensen P; Roux D; Maire P
Pathol Biol (Paris); 1996 Apr; 44(4):299-305. PubMed ID: 8763595
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetic study of teicoplanin in severely neutropenic patients.
Lortholary O; Tod M; Rizzo N; Padoin C; Biard O; Casassus P; Guillevin L; Petitjean O
Antimicrob Agents Chemother; 1996 May; 40(5):1242-7. PubMed ID: 8723474
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and toxicity of two dosing-regimens of amikacin in neonates with sepsis.
Abdel-Hady E; El Hamamsy M; Hedaya M; Awad H
J Clin Pharm Ther; 2011 Feb; 36(1):45-52. PubMed ID: 21198719
[TBL] [Abstract][Full Text] [Related]
5. Population Pharmacokinetics of Amikacin Administered Once Daily in Patients with Different Renal Functions.
Aréchiga-Alvarado NA; Medellín-Garibay SE; Milán-Segovia RDC; Ortiz-Álvarez A; Magaña-Aquino M; Romano-Moreno S
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32041715
[TBL] [Abstract][Full Text] [Related]
6. Estimation of once-daily amikacin dose in critically ill adults.
Šíma M; Hartinger J; Cikánková T; Slanař O
J Chemother; 2018 Feb; 30(1):37-43. PubMed ID: 28950787
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of meropenem in febrile neutropenic patients in Korea.
Lee DG; Choi SM; Shin WS; Lah HO; Yim DS
Int J Antimicrob Agents; 2006 Oct; 28(4):333-9. PubMed ID: 16942864
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of amikacin in a Korean clinical population.
Jang SB; Lee YJ; Park MS; Song YG; Kim JH; Kim HK; Ahn BS; Park K
Int J Clin Pharmacol Ther; 2011 Jun; 49(6):371-81. PubMed ID: 21612744
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of renal function equations to predict amikacin clearance.
Sáez Fernández EM; Pérez-Blanco JS; Lanao JM; Calvo MV; Martín-Suárez A
Expert Rev Clin Pharmacol; 2019 Aug; 12(8):805-813. PubMed ID: 31242039
[No Abstract] [Full Text] [Related]
10. Evaluation of Amikacin Pharmacokinetics and Pharmacodynamics for Optimal Initial Dosing Regimen.
Kato H; Hagihara M; Hirai J; Sakanashi D; Suematsu H; Nishiyama N; Koizumi Y; Yamagishi Y; Matsuura K; Mikamo H
Drugs R D; 2017 Mar; 17(1):177-187. PubMed ID: 28063020
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic variability of amikacin after once-daily and twice-daily dosing regimen in full-term neonates.
Vučićević K; Rakonjac Z; Miljković B; Janković B; Prostran M
J Pharmacol Sci; 2014; 124(2):138-43. PubMed ID: 24441865
[TBL] [Abstract][Full Text] [Related]
12. Effect of fever on pharmacokinetics and dosage regimen of intramuscularly administered amikacin in goats.
Agrawal AK; Singh SD; Jayachandran C
J Vet Sci; 2001 Aug; 2(2):91-6. PubMed ID: 14614277
[TBL] [Abstract][Full Text] [Related]
13. [Clinical, pharmacokinetic and therapeutic study of amikacin with single daily dose and in combination in neutropenic children with fever].
Bertrand Y; Bréant V; Vray C; Nakache C; Barbé G; Dürr F; Aulagner G
Arch Pediatr; 1996 Sep; 3(9):854-60. PubMed ID: 8949344
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic dosing of aminoglycosides: a controlled trial.
Bartal C; Danon A; Schlaeffer F; Reisenberg K; Alkan M; Smoliakov R; Sidi A; Almog Y
Am J Med; 2003 Feb; 114(3):194-8. PubMed ID: 12637133
[TBL] [Abstract][Full Text] [Related]
15. Quantification and Explanation of the Variability of First-Dose Amikacin Concentrations in Critically Ill Patients Admitted to the Emergency Department: A Population Pharmacokinetic Analysis.
De Winter S; van Hest R; Dreesen E; Annaert P; Wauters J; Meersseman W; Van den Eede N; Desmet S; Verelst S; Vanbrabant P; Peetermans W; Spriet I
Eur J Drug Metab Pharmacokinet; 2021 Sep; 46(5):653-663. PubMed ID: 34297338
[TBL] [Abstract][Full Text] [Related]
16. Nonparametric population pharmacokinetic analysis of amikacin in neonates, infants, and children.
Tréluyer JM; Merlé Y; Tonnelier S; Rey E; Pons G
Antimicrob Agents Chemother; 2002 May; 46(5):1381-7. PubMed ID: 11959572
[TBL] [Abstract][Full Text] [Related]
17. The pharmacokinetic of amikacin in critically ill adult and paediatric patients: comparison of once- versus twice-daily dosing regimens.
Marik PE; Havlik I; Monteagudo FS; Lipman J
J Antimicrob Chemother; 1991 May; 27 Suppl C():81-9. PubMed ID: 1856148
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China.
Zhang J; Xu JF; Liu YB; Xiao ZK; Huang JA; Si B; Sun SH; Xia QM; Wu XJ; Cao GY; Shi YG; Zhang YY
J Infect Chemother; 2009 Oct; 15(5):293-300. PubMed ID: 19856067
[TBL] [Abstract][Full Text] [Related]
19. Relative pharmacokinetics of three amikacin brands in onco-hemotologic pediatric patients experiencing febrile neutropeina.
Jamshaid M; Yousuf S; Bukhari NI; Rizvi AA
Eur J Drug Metab Pharmacokinet; 2003; 28(1):1-6. PubMed ID: 14503658
[TBL] [Abstract][Full Text] [Related]
20. An open prospective study of amikacin pharmacokinetics in critically ill patients during treatment with continuous venovenous haemodiafiltration.
D'Arcy DM; Casey E; Gowing CM; Donnelly MB; Corrigan OI
BMC Pharmacol Toxicol; 2012 Nov; 13():14. PubMed ID: 23136834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
